For the year ending 2025-12-31, DTIL had $28,685K increase in cash & cash equivalents over the period. -$65,928K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -45,724 |
| Depreciation and amortization | 1,468 |
| Share-based compensation | 10,186 |
| Impairment charges | 36 |
| (gain) loss on disposal of assets | -421 |
| Issuance of common stock in exchange for services | 259 |
| Non-cash interest expense | 186 |
| Amortization of right-of-use assets | 1,285 |
| Loss (gain) on changes in other fair value adjustments | -2,666 |
| Loss from equity method investment | -5,284 |
| Gain from disposal of business | 855 |
| Amortization of discount on note receivable | 682 |
| Gain on change in fair value of warrant liability | 11,129 |
| Prepaid expenses | -3,331 |
| Marketable securities | 4,536 |
| Convertible note receivable | 0 |
| Accounts receivable | -229 |
| Contract asset | -1,469 |
| Other assets and other current assets | -339 |
| Accounts payable | -737 |
| Other liabilities and other current liabilities | -1,762 |
| Deferred revenue | -26,257 |
| Lease liabilities | -1,320 |
| Net cash used in operating activities | -65,843 |
| Purchases of property, equipment and software | 85 |
| Purchases of intangibles assets | 615 |
| Proceeds from sale of equipment | 66 |
| Net cash used in investing activities | -634 |
| Proceeds from employee stock purchase plan | 218 |
| Proceeds from offering of common stock and warrants through underwritten offering, net of issuance costs | 69,980 |
| Proceeds from issuance of common stock through atm facility, net of issuance cost | 23,933 |
| Proceeds from offering of common stock to collaboration partners and licensees | 1,031 |
| Repayment of revolving credit facility | 0 |
| Borrowings from term loan debt facility, net of issuance costs paid to lender | 0 |
| Net cash provided by financing activities | 95,162 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,685 |
| Cash, cash equivalents, and restricted cashbeginning of period | 108,468 |
| Cash, cash equivalents, and restricted cash end of period | 137,153 |
PRECISION BIOSCIENCES INC (DTIL)
PRECISION BIOSCIENCES INC (DTIL)